precigen inc - PGEN
PGEN
Close Chg Chg %
6.39 -0.20 -3.13%
Closed Market
6.19
-0.20 (3.13%)
Volume: 4.35M
Last Updated:
Oct 23, 2026, 4:00 PM EDT
Company Overview: precigen inc - PGEN
PGEN Key Data
| Open $6.35 | Day Range 6.15 - 6.38 |
| 52 Week Range 3.04 - 8.98 | Market Cap $2.36B |
| Shares Outstanding 358.04M | Public Float 164.24M |
| Beta 0.92 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.09 |
| Yield 0.00% | Dividend $0.24 |
| EX-DIVIDEND DATE Jan 19, 2017 | SHORT INTEREST N/A |
| AVERAGE VOLUME 5.15M |
PGEN Performance
| 1 Week | -3.05% | ||
| 1 Month | -20.13% | ||
| 3 Months | 14.63% | ||
| 1 Year | 42.96% | ||
| 5 Years | 28.16% |
PGEN Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
4
Full Ratings ➔
About precigen inc - PGEN
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.
PGEN At a Glance
Precigen, Inc.
20374 Seneca Meadows Parkway
Germantown, Maryland 20876
| Phone | 1-301-556-9900 | Revenue | 9.68M | |
| Industry | Biotechnology | Net Income | -250,642,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 146.726% | |
| Fiscal Year-end | 12 / 2026 | Employees | 160 | |
| View SEC Filings |
PGEN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 135.095 |
| Price to Book Ratio | 70.74 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -12.656 |
| Enterprise Value to Sales | 135.139 |
| Total Debt to Enterprise Value | 0.075 |
PGEN Efficiency
| Revenue/Employee | 60,525.00 |
| Income Per Employee | -1,566,512.50 |
| Receivables Turnover | 2.22 |
| Total Asset Turnover | 0.064 |
PGEN Liquidity
| Current Ratio | 3.089 |
| Quick Ratio | 2.832 |
| Cash Ratio | 2.623 |
PGEN Profitability
| Gross Margin | 37.051 |
| Operating Margin | -1,100.785 |
| Pretax Margin | -2,588.176 |
| Net Margin | -2,588.207 |
| Return on Assets | -165.354 |
| Return on Equity | -571.968 |
| Return on Total Capital | -210.268 |
| Return on Invested Capital | -264.751 |
PGEN Capital Structure
| Total Debt to Total Equity | 470.04 |
| Total Debt to Total Capital | 82.457 |
| Total Debt to Total Assets | 62.757 |
| Long-Term Debt to Equity | 464.607 |
| Long-Term Debt to Total Capital | 81.504 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Precigen Inc - PGEN
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 26.91M | 6.22M | 3.92M | 9.68M | |
Sales Growth
| -74.09% | -76.87% | -36.95% | +146.73% | |
Cost of Goods Sold (COGS) incl D&A
| 11.14M | 10.97M | 7.33M | 6.10M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 7.19M | 6.67M | 4.53M | 3.20M | |
Depreciation
| 2.39M | 1.82M | 1.47M | 1.93M | |
Amortization of Intangibles
| 4.80M | 4.85M | 3.06M | 1.27M | |
COGS Growth
| -80.92% | -1.53% | -33.20% | -16.79% | |
Gross Income
| 15.77M | (4.74M) | (3.40M) | 3.59M | |
Gross Income Growth
| -65.33% | -130.07% | +28.28% | +205.50% | |
Gross Profit Margin
| +58.61% | -76.18% | -86.65% | +37.05% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 90.38M | 84.18M | 91.30M | 110.19M | |
Research & Development
| 47.17M | 48.61M | 50.01M | 40.06M | |
Other SG&A
| 43.21M | 35.57M | 41.29M | 70.13M | |
SGA Growth
| -27.27% | -6.86% | +8.46% | +20.68% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 159.00K | 10.78M | 40.32M | 143.43M | |
EBIT after Unusual Expense
| (74.77M) | (99.70M) | (135.03M) | (250.03M) | |
Non Operating Income/Expense
| 1.57M | 3.80M | 7.01M | 3.26M | |
Non-Operating Interest Income
| 133.00K | 3.24M | 1.42M | 3.21M | |
Equity in Earnings of Affiliates
| - | - | - | 862.00K | - |
Interest Expense
| 6.77M | 468.00K | 6.00K | 3.87M | |
Interest Expense Growth
| -64.14% | -93.09% | -98.72% | +64,350.00% | |
Gross Interest Expense
| 6.77M | 468.00K | 6.00K | 3.87M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (79.97M) | (96.36M) | (128.03M) | (250.64M) | |
Pretax Income Growth
| +17.50% | -20.50% | -32.86% | -95.77% | |
Pretax Margin
| -297.17% | -1,547.98% | -3,261.86% | -2,588.18% | |
Income Tax
| (189.00K) | (458.00K) | (1.79M) | 3.00K | |
Income Tax - Current - Domestic
| - | 21.00K | 2.00K | 3.00K | |
Income Tax - Current - Foreign
| - | - | - | (39.00K) | - |
Income Tax - Deferred - Domestic
| - | 48.00K | (327.00K) | (52.00K) | |
Income Tax - Deferred - Foreign
| - | (198.00K) | (152.00K) | (1.74M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | 862.00K | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (79.78M) | (95.90M) | (126.23M) | (250.64M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (79.78M) | (95.90M) | (126.23M) | (250.64M) | |
Net Income Growth
| +17.56% | -20.22% | -31.63% | -98.55% | |
Net Margin Growth
| -296.47% | -1,540.63% | -3,216.18% | -2,588.21% | |
Extraordinaries & Discontinued Operations
| - | - | - | 13.39M | - |
Discontinued Operations
| - | - | - | 13.39M | - |
Net Income After Extraordinaries
| (66.39M) | (95.90M) | (126.23M) | (250.64M) | |
Preferred Dividends
| - | - | - | 179.00M | - |
Net Income Available to Common
| (66.39M) | (95.90M) | (126.23M) | (429.64M) | |
EPS (Basic)
| -0.3313 | -0.3922 | -0.4715 | -1.3727 | |
EPS (Basic) Growth
| +28.91% | -18.38% | -20.22% | -191.13% | |
Basic Shares Outstanding
| 200.36M | 244.54M | 267.73M | 312.98M | |
EPS (Diluted)
| -0.3313 | -0.3922 | -0.4715 | -1.3727 | |
EPS (Diluted) Growth
| +28.91% | -18.38% | -20.22% | -191.13% | |
Diluted Shares Outstanding
| 200.36M | 244.54M | 267.73M | 312.98M | |
EBITDA
| (67.42M) | (82.25M) | (90.18M) | (103.40M) | |
EBITDA Growth
| -3.69% | -22.01% | -9.63% | -14.66% | |
EBITDA Margin
| -250.53% | -1,321.37% | -2,297.55% | -1,067.75% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 13.667 | |
| Number of Ratings | 4 | Current Quarters Estimate | 0.078 | |
| FY Report Date | 12 / 2026 | Current Year's Estimate | 0.171 | |
| Last Quarter’s Earnings | 0.05 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.37 | Next Fiscal Year Estimate | 0.636 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 3 | 2 | 3 | 4 |
| Mean Estimate | 0.08 | 0.17 | 0.17 | 0.64 |
| High Estimates | 0.11 | 0.26 | 0.23 | 1.32 |
| Low Estimate | 0.06 | 0.08 | 0.14 | 0.29 |
| Coefficient of Variance | 36.15 | 73.35 | 29.66 | 73.05 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 3 | 3 | 2 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Precigen Inc - PGEN
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Precigen Inc - PGEN
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Sep 25, 2026 | Harry Thomasian Chief Financial Officer | 268,993 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $4.72 per share | 1,269,646.96 |
| Sep 25, 2026 | Harry Thomasian Chief Financial Officer | 311,911 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $2.33 per share | 726,752.63 |
| Sep 25, 2026 | Harry Thomasian Chief Financial Officer | 311,913 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $0.96 per share | 299,436.48 |
| Sep 25, 2026 | Harry Thomasian Chief Financial Officer | 311,914 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $1.21 per share | 377,415.94 |
| Sep 25, 2026 | Harry Thomasian Chief Financial Officer | 169,256 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Sep 25, 2026 | Harry Thomasian Chief Financial Officer | 157,082 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Sep 25, 2026 | Harry Thomasian Chief Financial Officer | 46,813 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Sep 25, 2026 | Harry Thomasian Chief Financial Officer | 520,999 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |